The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic Novo Nordisk A/S (NYSE:NVO) reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized…
ices and manufacturing-related costs weighed on margins. Chief Executive Officer Mike Doustdar said the company is serving more than 46 million people with obesity and diabetes and is treating nearly 5 million people with its obesity therapies, about 70% more than a year earlier
Novo Nordisk also raised its full-year outlook following what Chief Financial Officer Karsten Munk Knudsen described as a better-than-expected start to 2026. Wegovy Pill Drives Volume Growth – Bearish Pressure Is Building Around These 3 Stocks The company highlighted continued momentum for its oral Wegovy treatment, which launched in the U.S. six months ago. Jamey Millar, executive vice president of U.S.
Operations, said Wegovy pill had exceeded 5 million total prescriptions and reached weekly prescriptions of 267,000 as of July 17. Millar said the product has captured about 90% of the U.S. oral obesity-medication market despite competition entering in early April. Roughly 80% of patients using Wegovy pill are new to GLP-1 treatment, according to the company, suggesting the therapy is expanding the market rather than solely switching patients from existing products. – As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner Most U.S.